ENO1 and hepatocellular carcinoma: Our studies suggest that therapeutic targetting strategies aimed at LncRNA P5848-ENO1 axis may have benefits for patients with HCC, especially given the role of EMT in metastasis, drug resistance, and poor prognosis.